Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...